SCHEMBL7604646

SCHEMBL7604646

COC(=O)OCOC(C)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.45
LMNA P02545 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
GAA P10253 2/20 0.36
MGAM O43451 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
CHRM5 P08912 2/20 0.36
CHRM1 P11229 2/20 0.36
CHRM3 P20309 2/20 0.36
TSHR P16473 2/20 0.36
PGR P06401 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
HTR1A P08908 1/20 0.36
CHRNB2 P17787 1/20 0.36
TBXA2R P21731 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12055300 0.89 SMN1; SMN2 (0.41) ALDH1A1LMNAHSD17B10KMT2AGAA
SCHEMBL322669 0.83
SCHEMBL17263569 0.82 ALDH1A1 (0.42) ALDH1A1LMNAHSD17B10MEN1KMT2A
SCHEMBL10249500 0.82 ALDH1A1 (0.42) ALDH1A1LMNAHSD17B10MEN1KMT2A
SCHEMBL10412614 0.79 ALDH1A1 (0.52) ALDH1A1LMNAHSD17B10GAAMGAM
SCHEMBL7602566 0.78 TSHR (0.50) ALDH1A1LMNAHSD17B10MEN1KMT2A
SCHEMBL4482989 0.78 GAA (0.52) ALDH1A1LMNAHSD17B10MEN1KMT2A
SCHEMBL807505 0.78
SCHEMBL18736731 0.78 GAA (0.52) ALDH1A1LMNAHSD17B10MEN1KMT2A
Acetic Acid SCHEMBL28767597 0.77 ALDH1A1 (0.53) ALDH1A1LMNAHSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3555095-B1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-04-12 EP disclosed
US-9427501-B2 Coatings with crystallized active agent(s) and methods SURMODICS, INC. (US) 2016-08-30 US disclosed
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 US disclosed
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 US disclosed
US-8241921-B2 Active agent eluting matrices with particulates SURMODICS, INC. (US) 2012-08-14 US disclosed
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-05-17 US disclosed
US-20100303878-A1 BIODEGRADABLE BIOACTIVE AGENT RELEASING MATRICES WITH PARTICULATES SURMODICS MD, LLC 2010-12-02 US disclosed
US-20100166829-A1 ACTIVE AGENT ELUTING MATRICES WITH PARTICULATES SURMODICS, INC. (US) 2010-07-01 US disclosed
US-7709049-B2 Methods, devices, and coatings for controlled active agent release SURMODICS, INC. (US) 2010-05-04 US disclosed
US-7253277-B2 Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes NANOSPHERE, INC. (US) 2007-08-07 US disclosed
US-20070101933-A1 Method and Apparatus for Coating of Substrates SURMODICS, INC. (US) 2007-05-10 US disclosed
US-20070054127-A1 SILANE COATING COMPOSITIONS, COATING SYSTEMS, AND METHODS Surmodics Coatings, LLC 2007-03-08 US disclosed
US-7186814-B2 Bioconjugate-nanoparticle probes NANOSPHERE, INC. (US) 2007-03-06 US disclosed
US-20070026037-A1 Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility Surmodics Coatings, LLC 2007-02-01 US disclosed
EP-0191507-B1 NEW 2-OXYIMINO-3-OXOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARATION THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-05-16 EP disclosed
EP-0057422-B1 NEW CEPHEM COMPOUNDS, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-10-12 EP disclosed
EP-0191507-A2 New 2-oxyimino-3-oxobutyric acid derivatives and process for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-08-20 EP disclosed
US-4452851-A BACTERICIDES, ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-06-05 US disclosed
EP-0057422-A2 New cephem compounds, processes for preparation thereof and pharmaceutical composition containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100166829-A1 ACTIVE AGENT ELUTING MATRICES WITH PARTICULATES MIF, CD47, CD68 ALDH1A1 1206/4885LMNA 866/4885HSD17B10 4185/4885
US-20070026037-A1 Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility CD47, GP6, MSN ALDH1A1 2441/4885LMNA 2808/4885HSD17B10 4318/4885
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE REN, AGTR1, AGTR2 ALDH1A1 484/4885LMNA 1723/4885HSD17B10 976/4885
US-20100303878-A1 BIODEGRADABLE BIOACTIVE AGENT RELEASING MATRICES WITH PARTICULATES BMP2, MIF, BMP1 ALDH1A1 3124/4885LMNA 2471/4885HSD17B10 3279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.